Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer

Aman U. Buzdar, Jordan U. Gutterman, George R. Blumenschein, Gabriel N. Hortobagyi, Charles K. Tashima, Terry L. Smith, Evan M. Hersh, Emil J. Freireich, Edmund A. Gehan

Research output: Contribution to journalArticle

50 Scopus citations

Abstract

For the past 34 months, a combination of 5‐fluorouracil, adriamycin, cyclophosphamide, and BCG (FAC‐BCG) was evaluated as adjuvant treatment in stage II and III breast cancer patients with positive axillary nodes. In the group of 131 patients receiving FAC‐BCG, the estimated proportion remaining disease‐free at 2 years from surgery was 91% compared to an estimated 69% in a group of 151 historical control patients (p < 0.01). This advantage was statistically significant in all subgroups except for patients with primary tumor less than 3 cm and for patients with less than 4 positive nodes. Estimated 2‐year survival rates were 96% for FAC‐BCG patients and 86% for control (p = 0.02). Treatment was well tolerated. Adjuvant FAC‐BCG seems effective in prolonging disease‐free interval and early survival in patients with stage II and III breast cancer. Its long term efficacy will require longer follow‐ups.

Original languageEnglish (US)
Pages (from-to)1064-1075
Number of pages12
JournalCancer
Volume41
Issue number3
DOIs
StatePublished - Mar 1978

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Buzdar, A. U., Gutterman, J. U., Blumenschein, G. R., Hortobagyi, G. N., Tashima, C. K., Smith, T. L., Hersh, E. M., Freireich, E. J., & Gehan, E. A. (1978). Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. Cancer, 41(3), 1064-1075. https://doi.org/10.1002/1097-0142(197803)41:3<1064::AID-CNCR2820410340>3.0.CO;2-Q